Thursday 28th September 2023 |
Text too small? |
AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Jon Lamb today retired from the board following his announcement at the ASM that he would be stepping down once a new independent director had been appointed. This is in conjunction with today’s appointment of Andrew Lane to the Board.
Chair David Flacks said: “On behalf of the Board I would like to extend my thanks to Jon for his outstanding service during his 11-year tenure. His deep industry knowledge and experience has enabled him to make a significant contribution to the growth and success of AFT, and it has been a privilege to work alongside him.”
Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.
For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232
About AFT Pharmaceuticals (ASX:AFP, NZX: AFT )
www.aftpharm.com
AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter, prescription, and hospital. AFT Pharmaceutical's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs.
No comments yet
CDC Independent Valuation - 30 June 2025
TruScreen Group Limited SPP Update
THL provides updated guidance
CEN - Greymouth gas deal
July 4th Morning Report
July 3rd Morning Report
ikeGPS Chief Financial Officer Transition
TWL - TradeWindow announces strategic partnership with FTA
BLT - Patent issue settled and new 5 year agreement with BSP
July 2nd Morning Report